Patent for Sale:

Extracorporeal Medical Device for the Treatment of Severe Sepsis    

Utilizes ultraviolet irradiation to inactivate blood-borne pathogens and hemofiltration to reduce inflammatory mediators.

Overview

The system is designed to treat blood-borne infectious diseases and overcome the inherent shortfalls of antibiotics and antivirals including: high cost, organism resistance, adverse patient reaction, and the time required to be effective. Severe sepsis is a multi-factorial disease and this technology has a unique, multi-factorial approach. Older approaches were “silver bullet” approaches and most clinicians believe that a “cocktail” approach is the only way a severe sepsis therapy can be successful. To date none of the “silver bullet” approaches have worked.

The technology will potentially be able to efficiently eradicate even the most drug resistant organisms by using the laws of physics rather than chemical (drug) reactions. The Company’s in vitro studies demonstrate that UV irradiation is 90 to 99 percent efficient in eliminating bacteria, while potentially allowing the body’s natural blood constituents to survive in a healthy state. Perhaps more importantly, the system is intended to make antibiotics currently used even more effective and improve patient outcomes. Used pro-actively, the Company believes that the system will lead to more economic and safer treatments for patients.

The technology is protected by 11 broad US patent and international patents. An additional patent has recently been allowed by the U.S. Patent Office.

Primary Application of the Technology

The primary application of this technology is for the treatment of severe sepsis. Over 200,000 patients per year die of sepsis. Sepsis is the 10th leading cause of death in the world, and is increasing in its frequency. The annual market opportunity for the technology is estimated at over $2 billion, and the technology offers potentially the most comprehensive cost effective approach available for the treatment of severe sepsis.

A market that is closely associated with sepsis is acute renal failure ("ARF"). ARF is a generic term defined as a decrease in renal function over a period of days. There are a number of causes of ARF, including septic shock, and despite hemodialysis and other advances in supportive care, mortality (when associated with multiple organ dysfunction), has remained high - ranging from 35% to greater than 90%. Use of this patented system to treat ARF is estimated to be a $500 million market.

Another market for this technology is avian flu. By modifying several product parameters it is expected that virus genetic material would be disrupted and the “cytokine storm” inherent with this flu would be attenuated.

Competitive Advantage

The seller believes that there are no directly competitive products on the market or in development.

The primary treatment for severe sepsis currently is antibiotic therapy. Typical treatment requires an extended hospital stay of 11 days, with much of this time being spent in the intensive care unit (ICU). Hospitals lose significant amounts of money on the treatment of septic patients and should thus be highly motivated to adopt a new therapy that both decreases the cost of treatment (by length of stay reduction) and reduces mortality. Some hospitals are unprofitable and may become profitable by adopting the patented system, especially when their annual severe sepsis caseload is above 200 patients. The seller believes that treatment of severe sepsis with the their system in conjunction with standard antibiotic therapy and other therapies will prove to be more effective than treatment with these therapies alone.

Comments on Deal Structure, Potential Terms and Restrictions

The preferred transaction is an outright sale of all assets associated with the technology, including patents, patent applications, two clinical prototype units, trade secrets and know-how.

The seller may consider selling these patents individually.

Patent Summary

U.S. Patent Classes & Classifications Covered in this listing:

Class 604: Surgery


European Patent Classes & Classifications Covered in this listing:

Class A61L2: HUMAN NECESSITIES - MEDICAL OR VETERINARY SCIENCE; HYGIENE

METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, O. Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor .

Class A61M1: HUMAN NECESSITIES - MEDICAL OR VETERINARY SCIENCE; HYGIENE

DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY . Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems .